Quarterly report [Sections 13 or 15(d)]

SEGMENT INFORMATION

v3.26.3
SEGMENT INFORMATION
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION

11. SEGMENT INFORMATION

 

The Company operates and manages its business as a single reporting segment. The business provides esoteric molecular diagnostic testing, and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer from clinical features. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. The Company’s chief operating decision maker (“CODM”) is the chief executive officer.

 

The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net income that is also reported on the condensed consolidated statements of operations. The monitoring of budgeted versus actual results is used in assessing performance of the segment and in establishing resource allocation across the organization.

 

The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets. All the Company’s long-lived assets are located in the United States. The accounting policies of the segment are the same as those described in Note 1, Nature of Business and Significant Accounting Policies included in our Annual Report on Form 10-K.

 

The following table presents reportable segment profit and loss, including significant expense categories, attributable to the Company’s reportable segment for the periods presented:

 

    2026     2025     2026     2025  
    For The Three Months Ended     For The Nine Months Ended  
    September 30,     September 30,  
    2026     2025     2026     2025  
                         
Revenue, net:   $ 10,373     $ 8,756     $ 28,537     $ 29,504  
Less:                                
Cost of revenue:                                
Fixed     1,754       1,736       5,220       5,120  
Variable     1,439       1,581       4,579       6,298  
Operating and other expenses:                                
Sales and marketing     2,704       2,087       7,088       7,811  
Research and development     160       150       461       500  
General and administrative     6,716       2,057       12,143       7,268  
Interest & other expense, net     (15 )     145       (33 )     268  
(Benefit) provision for income taxes     (884 )     (11 )     (517 )     7  
Segment net (loss) income     (1,501 )     1,011       (404 )     2,232  
Reconciliation of profit or loss:                                
Loss on discontinued operations     (109 )     (100 )     (327 )     (314 )
Consolidated net (loss) income   $ (1,610 )   $ 911     $ (731 )   $ 1,918  

 

Adjusted EBITDA, a non-GAAP financial measure, is a metric used by the CODM to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock-based compensation, non-recurring legal expenses, severance expense, asset impairment, interest and taxes, and other non-cash expenses including change in fair value of notes payable. The legal expenses included are related to NASDAQ uplist costs, special proxy and charter work, and an employment dispute. The table below includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

 

    2026     2025     2026     2025  
    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2026     2025     2026     2025  
(Loss) income from continuing operations (GAAP Basis)   $ (1,501 )   $ 1,011     $ (404 )   $ 2,232  
Depreciation and amortization     141       111       386       307  
Stock-based compensation     3,993       7       4,001       31  
Non-recurring legal expenses     234       -       614       -  
Severance & related expense     -       -       -       692  
Asset impairment - lab supplies     -       -       -       198  
Loss on sale of asset     104       -       104       -  
Lab supplies write-off     -       -       217       -  
Taxes (benefit) expense     (884 )     (11 )     (517 )     7  
Note payable interest     -       30       -       156  
Other income/expense, net     (15 )     10       (33 )     25  
Change in fair value of note payable     -       105       -       87  
Adjusted EBITDA   $ 2,072     $ 1,263     $ 4,368     $ 3,735